2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual
Technical Conferences
Merck Corporate Needs
NanoInk Symposium
Nano Electronics & Photonics
Nano Fabrication
MEMS & NEMS
Sensors & Systems
Micro & Nano Fluidics
MSM - Modeling Microsystems
WCM - Compact Modeling
Nanostructured Materials & Devices
Soft Nanotechnologies & Applications
Nanoparticles in Soft Materials - Colloidal Systems
Polymer Nanotechnology
Carbon Nano Structures & Devices
Nano Particles & Applications
Composites
Nanostructured Surfaces and Interfaces
Nanoscale Characterization
Energy Technologies & Applications
Nanotech in Health, Environment & Society
ICCN - Nanoscale Modeling
Nanoreliability
Bio Nano Materials & Tissues
Bio Sensors & Diagnostics
Biomarkers & Nanoparticles
Cancer Diagnostics, Imaging & Treatment
Drug Delivery & Therapeutics
Nano Medicine
Nanotech to Neurology
Phage Nanobiotechnology
Clean Technology 2008
Industrial Impact Workshop
Confirmed Speakers
Program Committee
Reviewers

Partnering Events:

TechConnect Summit
Clean Technology 2008
Mark N. Milton

Mark N. Milton

Vice President of Nonclinical Development
Tempo Pharmaceuticals

Mark Milton is Vice President of Nonclinical Development at Tempo Pharmaceuticals, Inc. Mark was educated in the United Kingdom, receiving a B.Sc. in Biochemistry and Soil Science from UCNW Bangor in 1982, M.Sc. in Toxicology in 1983 from the University of Surrey and Ph.D. in Biochemical Toxicology in 1989 from the University of Surrey. Following a Post Doc at the University of Illinois at Champaign-Urbana, he began his career in the pharmaceutical industry in 1991 at GD Searle in Skokie, Illinois. After 10 years Mark moved to Millennium Pharmaceuticals in Cambridge, MA. Mark joined Tempo in March 2007 as VP of Nonclinical Development with responsibility for Toxicology, Drug Metabolism and Pharmacokinetics, Early Clinical Development and Regulatory Affairs. Mark has extensive experience in the development of both small molecule pharmaceuticals and biologics, including Celebrex, Inspra and Velcade. He has made numerous presentations on the contributions of drug metabolism and pharmacokinetics to the effective development of novel pharmaceuticals.

Speaking in the special symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.


View Confimed Speakers

← Back to Conferences & Symposia